Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved..
Transplant glomerulopathy (TG) is generally accepted to result from repeated episodes of endothelial activation, injury and repair, leading to pathological abnormalities of double contouring or multi-layering of the glomerular basement membrane. TG is a major sequel of chronic active antibody-mediated rejection (cABMR), from pre-existing or de novo anti-HLA antibodies. Hepatitis C infection, thrombotic microangiopathy or other factors may also contribute to TG development. TG prevalence is 5-20% in most series, reaching 55%, in some high-risk cohorts, and is associated with worse allograft outcomes. Despite its prevalence and clinical significance, few well-studied treatment options have been proposed. Similar to desensitization protocols, plasmapheresis with or without immunoabsorption, high-dose intravenous immunoglobulin, rituximab, bortezomib and eculizumab have been proposed in the treatment of TG due to cABMR individually or in various combinations. Robust clinical trials are urgently needed to address this major cause of allograft loss. This review summarizes the current knowledge of the epidemiology, etiology, pathology, and the preventive and treatment options for TG secondary to cABMR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 30(2015), 11 vom: 01. Nov., Seite 1825-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Remport, Adam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic active antibody-mediated rejection |
|---|
| Anmerkungen: |
Date Completed 07.06.2016 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1093/ndt/gfu371 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM244265453 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244265453 | ||
| 003 | DE-627 | ||
| 005 | 20231224134332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ndt/gfu371 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0814.xml |
| 035 | |a (DE-627)NLM244265453 | ||
| 035 | |a (NLM)25473123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Remport, Adam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. | ||
| 520 | |a Transplant glomerulopathy (TG) is generally accepted to result from repeated episodes of endothelial activation, injury and repair, leading to pathological abnormalities of double contouring or multi-layering of the glomerular basement membrane. TG is a major sequel of chronic active antibody-mediated rejection (cABMR), from pre-existing or de novo anti-HLA antibodies. Hepatitis C infection, thrombotic microangiopathy or other factors may also contribute to TG development. TG prevalence is 5-20% in most series, reaching 55%, in some high-risk cohorts, and is associated with worse allograft outcomes. Despite its prevalence and clinical significance, few well-studied treatment options have been proposed. Similar to desensitization protocols, plasmapheresis with or without immunoabsorption, high-dose intravenous immunoglobulin, rituximab, bortezomib and eculizumab have been proposed in the treatment of TG due to cABMR individually or in various combinations. Robust clinical trials are urgently needed to address this major cause of allograft loss. This review summarizes the current knowledge of the epidemiology, etiology, pathology, and the preventive and treatment options for TG secondary to cABMR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic active antibody-mediated rejection | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a transplant glomerulopathy | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Isoantibodies |2 NLM | |
| 700 | 1 | |a Ivanyi, Bela |e verfasserin |4 aut | |
| 700 | 1 | |a Mathe, Zoltan |e verfasserin |4 aut | |
| 700 | 1 | |a Tinckam, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Mucsi, Istvan |e verfasserin |4 aut | |
| 700 | 1 | |a Molnar, Miklos Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |d 1990 |g 30(2015), 11 vom: 01. Nov., Seite 1825-33 |w (DE-627)NLM012639206 |x 1460-2385 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2015 |g number:11 |g day:01 |g month:11 |g pages:1825-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ndt/gfu371 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2015 |e 11 |b 01 |c 11 |h 1825-33 | ||